By Megan Leonhardt

Law360, New York (November 04, 2011, 2:20 PM ET) -- Pharmaceutical giant Novartis Pharmaceuticals Corp. lodged a patent infringement suit in Delaware on Thursday, seeking to stop Actavis Inc. from marketing a generic form of Novartis’ Exelon patch used to treat dementia patients.

Novartis and patent co-owner LTS Lohmann Therapie-Systeme AG claim generic-drug maker Actavis’ abbreviated new drug application filed with the U.S. Food and Drug Administration infringes three patents covering the Exelon patch.

“By filing its ANDA…for the purpose of obtaining approval to engage in the commercial manufacture, use, or sale of Actavis’ [generic Exelon...